Abstract:Abstract Cell-cell interactions within the tumor microenvironment play critical roles in tumor progression and its response to various therapies. Specifically in the case of pancreatic cancer, pancreatic cancer cells (PCCs) act on pancreatic stellate cells (PSCs), a major stromal cell type within the pancreatic tumor microenvironment, to provoke their transformation into and sustain an activated state, while activated PSCs interact with PCCs to promote tumor progression and confer a favorable environment for PCC resistance to immunosuppression and therapeutic treatment, setting up a vicious cycle. Therefore, effectively attacking the stromal PSCs alone or together with tumor cells may offer a new therapeutic route for pancreatic ductal adenocarcinoma (PDA) treatment. To identify key signaling molecules or pathways activated as a result of PSC-PCC interactions that might be targeted in pancreatic cancer as novel therapies, we developed unbiased quantitative mass spectrometry (MS)-based proteomics strategies to perform systemic analysis. Our comprehensive molecular and cellular analysis of in vitro PSC and PSC co-culture unraveled many interesting secreted proteins, either known or unknown previously, involved in the paracrine PCC-PSC crosstalk. We mainly focused on an intriguing signaling loop, in which PCCs secrete PDGFs that act on PSCs to promote the production of inflammatory cytokines by PSCs, including IL-6 family members, and especially LIF. These cytokines then act on PCCs to stimulate STAT3 activation, a known critical event for PDA initiation and progression. Significantly increased production of the cytokines and expression of corresponding receptors in both mouse and human PDA tumor contexts at both mRNA and protein levels were confirmed using various techniques. To further evaluate the functional significance of LIF in paracrine regulation of PDA progression in vivo, we exploited therapeutic blockage of the signaling using neutralizing mAbs and specific small molecule inhibitors in the classical KPC mouse PDA model. Our preclinical studies revealed significant efficacy of an anti-LIF mAb in increasing sensitivity to the standard-of-care chemotherapeutic gemcitabine, reducing tumor progression and prolonging survival of KPC mice. Currently, the molecular mechanisms underlying this sensitization are being investigated. Genetic studies using LIF receptor conditional knockout mice were also performed and showed significant beneficial effects. Furthermore, potential correlations between tissue or serum LIF and IL-6 cytokine levels and overall survival of human patients are also being evaluated. Citation Format: Yu Shi, Ruijun Tian, Tony Hunter.{Authors}. Interdicting the cytokine-mediated paracrine communication between pancreatic cancer and stellate cells as a new treatment approach for pancreatic ductal adenocarcinoma. [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care; 2016 May 12-15; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2016;76(24 Suppl):Abstract nr B27.

Paracrine Il-6 Signaling Mediates the Effects of Pancreatic Stellate Cells on Epithelial-Mesenchymal Transition Via Stat3/Nrf2 Pathway in Pancreatic Cancer Cells

IL-6/STAT3 Plays a Regulatory Role in the Interaction Between Pancreatic Stellate Cells and Cancer Cells

The Critical Roles of Activated Stellate Cells-Mediated Paracrine Signaling, Metabolism and Onco-Immunology in Pancreatic Ductal Adenocarcinoma

Pancreatic Stellate Cells Promote Epithelial-Mesenchymal Transition in Pancreatic Cancer Cells

The Effects and Mechanism of IL-6 on the Epithelial to Mesenchymal Transition of Pancreatic Cancer Cells

Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner

Tumor-stromal IL-1β/ NFκB / ESE3 Signaling Axis Drives Pancreatic Cancer Fibrosis, Chemoresistance, and Poor Prognosis

The P2X7 Receptor Stimulates IL-6 Release from Pancreatic Stellate Cells and Tocilizumab Prevents Activation of STAT3 in Pancreatic Cancer Cells

ESE3-positive PSCs Drive Pancreatic Cancer Fibrosis, Chemoresistance and Poor Prognosis Via Tumour-Stromal IL-1/NF-B/ESE3 Signalling Axis

Activation Ofpancreatic Stellate Cells Involves an EMT-like Process

The Effects and Mechanisms of Blockage of Stat3 Signaling Pathway on Il-6 Inducing Emt in Human Pancreatic Cancer Cells in Vitro

Soluble Factors from Stellate Cells Induce Pancreatic Cancer Cell Proliferation Via Nrf2-Activated Metabolic Reprogramming and Ros Detoxification

Abstract B27: Interdicting the Cytokine-Mediated Paracrine Communication Between Pancreatic Cancer and Stellate Cells As a New Treatment Approach for Pancreatic Ductal Adenocarcinoma

Curcumin Inhibits Pancreatic Cancer Cell Invasion and EMT by Interfering with Tumor‑stromal Crosstalk under Hypoxic Conditions Via the IL‑6/ERK/NF‑κB Axis.

Molecular Mechanism of Pancreatic Stellate Cells Activation in Chronic Pancreatitis and Pancreatic Cancer

STAT3 in tumor fibroblasts promotes an immunosuppressive microenvironment in pancreatic cancer

Gp130-Mediated STAT3 Activation Contributes to the Aggressiveness of Pancreatic Cancer through H19 Long Non-Coding RNA Expression

ESE3-positive PSCs drive pancreatic cancer fibrosis, chemoresistance and poor prognosis via tumour–stromal IL-1β/NF–κB/ESE3 signalling axis

Pancreatic Stellate Cells: Partners in Crime with Pancreatic Cancer Cells

The pro-inflammatory cytokines IL-1β and IL-6 promote upregulation of the ST6GAL1 sialyltransferase in pancreatic cancer cells

Pancreatic stellate cells: A dynamic player of the intercellular communication in pancreatic cancer